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Abstract
A validated method for assessing hemostasis in vivo is critical for testing the hemostatic efficacy
of therapeutic agents designed for patients with bleeding disorders such as von Willebrand disease
(VWD) and hemophilia A. We hypothesize that rate of bleeding and time to hemostasis can be
monitored in vivo by acoustic radiation force impulse (ARFI) ultrasound. We performed ARFI
imaging following 12-gauge needle puncture of hind limb muscle encompassing an ~2mm vein in
six normal, eight naïve hemophilia A before and after infusing canine factor VIII, three
hemophilia A expressing canine factor VIIa following gene transfer, and two naïve VWD dogs.
Serial data sets were processed with custom software to (1) estimate the rate of hemorrhage and
(2) estimate the time of hemostasis onset. The rate of hemorrhage during the first 30 min
following puncture was markedly increased in the VWD dogs relative to normal but was not
significantly different between normal, naïve hemophilia A or hemophilia A expressing cFVIIa.
ARFI-derived times to hemostasis were significantly longer in naïve hemophilia A dogs than in
normal dogs and were shortened by canine coagulation factors VIII and VIIa. These data support
our hypothesis that rate of hemorrhage and time to hemostasis in vivo in response to a
standardized hemostatic challenge can be detected by ARFI ultrasound in canine models of VWD
and hemophilia. These data also suggest that the ARFI-monitored hemostatic challenge is relevant
for in vivo testing of the hemostatic efficacy of therapeutic clotting factor replacement products
used to treat inherited bleeding disorders.
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INTRODUCTION
Hemophilia A and von Willebrand disease (VWD) are the most prevalent inherited bleeding
disorders in humans. Hemophilia A occurs in approximately one in 5000 live male births
and VWD in up to 1% in some populations (Rodeghiero et al. 1987; Mannucci and
Tuddenham 2001; Federici 2007). Typically, patients with severe hemophilia suffer from
spontaneous bleeding into joints, muscles and internal organs. Patients with VWD
experience easy bruising and excessive bleeding from minor cuts and scratches, as well as
bleeding from the mucous membranes of the nose, mouth and gastrointestinal tract (Kroll et
al. 2001). Despite marked improvements in currently available (clotting factor replacement
products [therapeutic clotting factor preparations that supply the deficient or anti-hemophilic
protein to treat or prevent bleeding]), these inherited bleeding disorders are life-long and
result in impaired quality of life, increased morbidity and mortality rates, extraordinary
health care costs, significant health disparities and continued threat of exposure to infectious
agents.
Documenting the hemostatic efficacy of new interventions to treat bleeding in hemophilia
and VWD is hobbled by the lack of a validated method for assessing hemostasis in vivo. In
general, hemophilia and VWD dog models, which closely resemble the respective human
disorders, have been an outstanding preclinical predictor of the safety and efficacy of new
treatments (Denis and Wagner 1999; Rawle and Lillicrap 2004; Nichols et al. 2009).
Historically, to document hemostatic efficacy in vivo, the primary saline bleeding time has
been used in VWD (Nichols et al. 2011) and the secondary cuticle bleeding time has been
used in hemophilia (Brinkhous et al. 1985, 2002). Both tests are difficult to reproduce in a
given dog and vary greatly among dogs (Brinkhous et al. 1985, 1989, 2002). The lack of a
validated, easily reproducible in vivo test of hemostasis is one of the major reasons that ex
vivo plasma based assays are accepted as a surrogate test of in vivo hemostasis. In fact, these
plasma assays only detect the presence of clotting factor activity and do not measure
hemostasis in vivo.
In this article, hemorrhage and bleeding are used interchangeably and are defined as the
escape of blood from a vessel. Bleeding into muscles either spontaneously or following
trauma to small veins and capillaries occurs in hemophilia (Ahlberg 1965; Bolton-Maggs
and Pasi 2003) and severe type 3 VWD (Sadler et al. 2006; Federici 2007). Hemostasis is
defined as the cessation of hemorrhage consisting of a primary phase, which includes a
vasoconstrictive component and von Willebrand factor (VWF)–mediated platelet adhesion
to sites of vessel injury (Sadler 2005; Nichols et al. 2008; Sadler 2008) and a secondary
phase, which involves the generation of cross-linked insoluble fibrin in a tissue factor-
initiated thrombin-mediated process (Monroe et al. 2002; Mackman et al. 2007). VWD is a
disorder of primary hemostasis characterized by impaired platelet adhesion and (manifested
phenotypically by excessive bleeding) that starts at the time of an injury. Hemophilia is a
disorder of secondary hemostasis characterized by impaired thrombin generation and
(manifested phenotypically by excessive bleeding) that is often delayed for variable amounts
of time following an injury.
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We have previously demonstrated acoustic radiation force impulse (ARFI) ultrasound, an
ultrasonic method for noninvasively interrogating the mechanical properties of tissue, for
distinguishing subcutaneous and periarterial hemorrhage at femoral artery punctures in
patients undergoing cardiac catheterization (Behler et al. 2009a, 2009b). We have now
progressed to applying ARFI to monitoring rate of bleeding and detecting hemostasis
following a standardized hemostatic challenge in relevant canine models of hemophilia A
and VWD. Our data support ARFI’s relevance to monitoring hemorrhage and hemostasis in
vivo especially in preclinical testing of therapeutic agents.
METHODS
All dogs were treated according to the standards set in the Guide for Care and Use of
Laboratory Animals (National Institutes of Health publication No. 85–23). All procedures
and protocols were in accordance with institutional guidelines and approved by the
Institutional Animal Care and Use Committee. All dogs were produced and maintained at
the Francis Owen Blood Research Laboratory at the University of North Carolina at Chapel
Hill. Dogs entered into this study were fully anesthetized with isoflurane to effect (usually
~2%) with constant monitoring of blood pressure, oxygen saturation and core body
temperature. The dogs were placed in a prone position and the hind limb was shaved and
prepped with an aseptic method, then, tethered to the table to prevent motion during
imaging. The ultrasound transducer, held in place with a stereotactic clamp, was positioned
above a peripheral vein (~2 mm diameter) in the hind limb. A standardized hemostatic
challenge was performed as follows: with ultrasound image guidance, a 12-gauge needle
was used to puncture the hind limb muscle and vein five repeated times (Fig. 1). ARFI data
and a spatially matched B-mode frame were serially acquired immediately before puncture,
every minute for the first 15 min following puncture, every 2 min from 15 to 25 min, then
every 5 min thereafter for a total imaging period of 100 min.
This hemostatic challenge coupled with ARFI imaging (to detect the rate of bleeding and
time to hemostasis in the response to the hemostatic challenge) has been performed in the
following series of dogs: normal (n = 6), naïve hemophilia A monitored for 30 min of
bleeding then infused with canine FVIII to 11.3 ± 1.8% activity (Chromogenix, n = 8) to
prevent formation of large hematomas, hemophilia A expressing canine factor FVIIa at 1.3–
2 μg/mL (cFVIIa, n = 3) (Margaritis et al. 2009) and naïve VWD (n = 2). The three
hemophilia A dogs expressing cFVIIa underwent the full protocol twice, with imaging
events 2 to 3 months apart.
ARFI imaging was performed using a Siemens SONOLINE Antares™ imaging system
specially equipped for research purposes (Siemens Medical Solutions USA, Inc., Ultrasound
Division) and a VF7-3 linear array transducer. The ARFI beam sequence consisted of two
conventional two-cycle reference A-lines, followed by a 300-cycle (70 μs) ARFI excitation
impulse centered at 4.21 MHz, with an F/1.5 focal configuration. The excitation was
followed by an ensemble of 60 (6 ms) conventional A-lines at a center frequency of 6.15
MHz and prf of 11 kHz. This ensemble was repeated in 40 locations spaced 0.53 mm apart
laterally for a 2.1 cm lateral field of view (FOV). The focal depth was positioned on the near
venous wall, typically 22 mm in depth. A 2 cm standoff pad was used as needed to optimize
imaging.
Acquired RF data was transferred to a computational workstation for processing and
analysis. One-dimensional (1-D) axial displacements were estimated along each acquired
ensemble using cross-correlation with a 1.5 λ kernel, an interpolation factor of 4 and a
search window length of 80 μm (Pinton et al. 2006). Physiologic motion was rejected using
a linear filter applied to the measured ARFI displacement profiles (Behler et al. 2007).
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Signal from hemorrhage was isolated using custom software (Scola et al. 2009). Our
algorithm exploited measured 1-D axial displacements through time of ensemble acquisition
and a priori information regarding soft tissue, hemorrhage and luminal blood displacement
characteristics. Soft tissue was expected to have recovered by 4 ms after ARFI excitation,
whereas hemorrhage was not expected to have recovered by 4 ms and luminal blood was
expected to be flowing uninterrupted. Thus, it was anticipated that axial displacements
measured 4 ms after ARFI excitation in the soft tissue would have low variance relative to
hemorrhage. Similarly, the displacement variance of hemorrhage was anticipated to be low
relative to luminal blood. These displacement characteristics are illustrated in Figure 1,
which shows plots of displacement versus time (panel b) and second derivative of
displacement vs. time (panel c) for representative hemorrhage (top), muscle and soft tissue
(middle) and luminal blood (bottom) pixels. The second time derivative, a high-pass
filtering operation (Bovik 2005), of hemorrhage has high variance relative to that of the soft
tissue but low variance relative to that of luminal blood. An empirically derived upper
threshold (on the variance of the second time derivative of displacement) was applied to
exclude luminal blood, and an empirically derived lower threshold was applied to exclude
soft tissue. The remaining pixels, identified as hemorrhage, were colored red on the matched
B-mode images to create an ARFI/B-Mode hybrid image (Fig. 2).
Hemorrhage area was estimated by the number of identified hemorrhage pixels multiplied
by 0.01 mm2, the spatial area spanned by each pixel. Plots of hemorrhage area vs. time were
divided into 10-min intervals and fit using a linear-least squares approximation. The slope of
each line segment was recorded as the hemorrhage rate of that 10-min interval and the time
to 75% maximum hemorrhage area was defined as an approximation of time to hemostasis
onset, as described by Figure 2.
Statistical analysis
Statistical analyses were performed in R (R Foundation for statistical computing, Vienna).
The two-sample t-test was the primary tool for comparing the differences of mean bleeding
rate and time to hemostasis among the four groups. However, the two-sample Wilcoxon test
with continuity correction was used to compare the differences of time to hemostasis
between the normal group and the naïve hemophilia A group. Statistical significance was
assumed for p values below 0.05.
RESULTS
ARFI-derived bleeding rates calculated over the first 30 min following puncture, depicted in
Figure 3, were markedly increased in the VWD dogs relative to normal by a factor of ~3(n =
2, p = 0.0009) (Table 1). Bleeding rates were not significantly different between normal
dogs, hemophilia A dogs expressing cFVIIa at 1.3–2 μg/mL and naïve hemophilia A dogs
before or after infusing cFVIII. The early data from these two VWD dogs suggest that the
ARFI-derived bleeding rate will be applicable for detecting abnormal rates of bleeding in
disorders of primary hemostasis and potentially for testing the hemostatic efficacy in vivo of
relevant therapeutic agents.
ARFI-derived times to hemostasis, depicted in Figure 4, were significantly different between
normal and naïve hemophilia A dogs (Table 1, p < 0.00078). Administration of FVIII to
11.3 ± 1.8% of normal to treat the induced bleeding in these eight hemophilia A dogs
shortened the time to hemostasis but to a range that was still significantly different than
normal dogs (p < 0.036). Notably, expression of FVIIa at 1.3–2 μg/mL significantly
shortened the time to hemostasis relative to naïve hemophilia A (p < 0.027), though the
value was significantly different than normal dogs (p < 0.025). The dogs expressing FVIIa
required no additional treatment to support hemostasis, a profound improvement in bleeding
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phenotype. Our time to hemostasis data points from two VWD dogs do not allow us to
detect a relationship relative to normal dogs. These data support using the ARFI-derived
time to hemostasis as an endpoint for detecting disorders of secondary hemostasis and for
testing the hemostatic efficacy in vivo of relevant therapeutic agents.
Mean systolic and diastolic blood pressures during the imaging period for the five dog
groups are reported in Table 1. Systolic pressures were not statistically significantly (p >
0.05) different across dogs and neither were diastolic pressures. These data suggest that the
impact of blood pressure on rate of hemorrhage and time to hemostasis was minimized by
maintaining comparable systolic (108.05–154.11 mm Hg) and comparable diastolic (57.81–
103.41 mm Hg) blood pressures for all dogs during the hemostatic challenge and ARFI
monitoring period. Oxygen saturation was maintained above 90% and core body
temperature was maintained between 100 and 102°C (normal range for dogs).
DISCUSSION
We hypothesized that rate of bleeding and time to hemostasis could be monitored in vivo by
ARFI ultrasound. We have detected significant differences in the rate of bleeding between
normal and VWD dogs. Also, significantly longer times to hemostasis were detected in
naïve hemophilia A dogs relative to normal. These data support our hypothesis and provide
justification for validating the ARFI monitored hemostatic challenge as an in vivo test of
hemostasis. Because no comparable in vivo test for hemostasis is currently available, we
were unable to compare our measurements with published values for time to hemostasis and
rate of hemorrhage.
Von Willebrand factor mediates platelet adhesion at sites of endothelial disruption,
especially under high shear conditions (Sadler 2005, 2008; Nichols et al. 2008). The primary
hemostatic defect that is phenotypically characteristic of VWD is most likely due to
inadequate formation of a platelet plug at sites of vascular perforation. Our results have
shown markedly increased rates of bleeding with the ARFI monitored hemostatic challenge
when VWD dogs are compared with normal or hemophilia A. Although the finding of
increased rates of bleeding in VWD will need to be confirmed in additional VWD dogs,
these preliminary observations support the hypothesis that increased rate of bleeding with
this hemostatic challenge is due to a defect in primary hemostasis resulting from the absence
of VWF. Confirmation of this hypothesis will require determining if normalization of the
defect in primary hemostasis can be accomplished by replacement of VWF function in these
VWD dogs.
In contrast to VWD, hemophilic subjects have normal VWF levels and, therefore, normal
VWF-mediated platelet plug formation but have a failure of secondary hemostasis (Kazazian
et al. 2001; Bolton-Maggs and Pasi 2003). Impaired or absent coagulation factor VIII in
hemophilia A results in inadequate amounts of thrombin formation and, consequently,
defective stabilization of the platelet plug by fibrin. Our results have shown significantly
longer time to hemostasis in hemophilia A with the ARFI monitored hemostatic challenge
when naïve hemophilia A dogs are compared with normal. Most importantly, infusion of
cFVIII to 11.3 ± 1.8% of normal activity markedly shortened the time to hemostasis and
expression of cFVIIa at therapeutic levels (Brinkhous et al. 1989; Margaritis et al. 2009)
shortened the time to hemostasis to the range found in normal dogs. Further studies are
planned to determine if infusion of higher levels of cFVIII in hemophilia A dogs would
support a time to hemostasis more like that in normal dogs. Also of note, the hemophilia A
dogs expressing cFVIIa required no additional therapeutic agents (i.e., cFVIII) to support
hemostasis. This result suggests that expression of cFVIIa by gene therapy supports
hemostasis in vivo and corroborate the correction of the hemophilic phenotype observed in
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these dogs with the partial correction of the whole blood clotting time and absence of
spontaneous bleeding events (Margaritis et al. 2009). Bleeding in naïve hemophilia A dogs
was limited to a 30-min observation period, after which time the cFVIII was administered to
the dogs to prevent the formation of a large hematoma. This approach did not allow us to
measure times to hemostasis beyond 30 min in the naïve hemophilia A dogs. Notably, none
of the eight naïve hemophilia A dogs had achieved hemostasis by 30 min according to our
ARFI definition. These findings support the hypothesis that in naïve hemophilia A, the time
to hemostasis with this hemostatic challenge is due to a defect in secondary hemostasis due
to the absence of FVIII and impaired thrombin formation. The corollary is that support of
thrombin formation by infusion of cFVIII or FVIIa improved secondary hemostasis reflected
in the reduced ARFI-derived times to hemostasis.
As with any radiation-force-based application, it is important to be mindful of potential
thermal or mechanical bioeffects. Heating associated with our applied ARFI excitation
impulses is estimated to be 0.06°C in human tissue, neglecting perfusion and other cooling
effects (Palmeri et al. 2004; Palmeri and Nightingale 2004). In addition, we measured
mechanical displacements of less than 10 μm in areas of blood. We, therefore, do not expect
that clotting times were affected by either heating or by mechanical disturbances induced by
ARFI.
One source of error in our results is a limited two-dimensional (2-D) field of view (FOV). It
is apparent in Figure 2 that hemorrhage areas extend beyond the white vertical lines, which
demarcate the ARFI lateral range. Hemorrhage outside the ARFI lateral range would result
in smaller detected hemorrhage areas and may distort time to hemostasis and hemorrhage
rate estimates. We will consider broadening the ARFI lateral range in future studies. Despite
this error, our time to hemostasis and hemorrhage rate estimates follow the trends expected
for established hemophilia A and VWD phenotypes.
An area for enhanced performance of in vivo ARFI hemostasis assessment is three-
dimensional (3-D) imaging. Three-dimensional imaging could improve estimation of time to
hemostasis and hemorrhage rate by monitoring hemorrhage volume as opposed to cross-
sectional area. Hemorrhage volume is likely to be a more accurate indication of active
bleeding given the asymmetric geometries of hematomas. Three-dimensional ARFI imaging
would also support quantification of hemorrhage volume, a clinically meaningful metric
(Gutierrez et al. 2004).
CONCLUSIONS
This preclinical pilot feasibility study in relevant canine models of inherited bleeding
disorders supports that ARFI ultrasound is a viable imaging method for in vivo detection of
rate of hemorrhage and onset of hemostasis following a standardized hemostatic challenge.
These results are consistent with our previous pilot clinical demonstration of ARFI imaging
for evaluating hemostasis at femoral artery puncture, which showed shortened ARFI-derived
times to hemostasis with application of a hemostatic dressing relative to standard of care
manual compression alone (Behler et al. 2009b). This work strongly supports ARFI’s
relevance for assessing the hemostatic efficacy in vivo of therapies for inherited bleeding
disorders. A rational extension of this work would be to apply ARFI monitoring of
hemorrhage in acquired bleeding disorders such as with antiplatelet and anticoagulant
therapies, massive trauma or surgery.
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Methods of blood signal detection in acoustic radiation force impulse (ARFI) ultrasound. (a)
The imaging transducer is positioned above punctured muscle and surrounding soft tissue
and small (~2 mm) vein. (b) ARFI displacement profiles arising from regions of hemorrhage
and tissue (top), muscle and soft tissue alone (middle) and luminal blood (bottom) exhibit
late displacement variations (boxed) that are highlighted by (c) the second time derivative.
(d) Applying upper and lower thresholds to the variance of the second time derivative of
displacement distinguishes hemorrhage from soft tissue and luminal blood.
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Methods of acoustic radiation force impulse (ARFI)hemorrhage rate and time to hemostasis
estimation. (Bottom row) In serially acquired ARFI frames in a naïve hemophilia A dog,
hemorrhage pixels (red) are identified (Fig. 1) and associated cross-sectional area (CSA)
calculated. (Top graph) CSA is plotted versus time of image acquisition (blue dots). The
CSA plot is subdivided into 10 min intervals and a line is fit using a linear least-squares
regression approximation (red lines). The slopes of the lines are recorded as the hemorrhage
rate (mm2/min). Time to hemostasis onset is estimated as time to 75% of the maximum
observed hemorrhage CSA. Please note, the dog was infused with cFVIII to 11.3 ± 1.8%, at
30 min.
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Acoustic radiation force impulse (ARFI)-derived hemorrhage rate. Box-plot displaying the
median (red-line), 25th and 75th percentiles (blue box), range of observed values (dashed
black lines) and outliers (red “plus”) for the hemorrhage rate in the first 30 min following
puncture for all normal, naïve hemophilia A, naïve hemophilia A treated with FVIII to 11.3
± 1.8%, cFVIIa expressing hemophilia A and naïve Willebrand disease (VWD) dogs.
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Acoustic radiation force impulse (ARFI)-derived time to hemostasis. Box-plot displaying
the median (red-line), 25th and 75th percentiles (blue box) and range of observed values
(dashed black lines) for the time to hemostasis for all normal, naïve hemophilia A, naïve
hemophilia A treated with FVIII to 11.3 ± 1.8%, cFVIIa expressing hemophilia A and naïve
Willebrand disease (VWD) dogs.
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Table 1
Bleeding rates and time to hemostasis from ARFI-monitored hemostatic challenge by dog phenotype (mean ±
standard deviation)





Mean BP (mm Hg)
1. Normal 6 0.6174 ± 0.33254‡ 17.52 ± 6.05§ 134.38/82.69 ± 18.41/21.16¶
2. Naïve hemophilia A 8 0.86887 ± 0.39963‡ >30§ 128.20/77.37 ± 10.59/16.89¶
3. Naïve hemophilia A treated with FVIII
  to 11.3 ± 1.8% 8 0.60819 ± 0.32415
‡ 28.40 ± 12.39§ 135.98/88.27 ± 8.24/13.28¶
4. Hemophilia A expressing FVIIa
  (Margaritis et al. 2009) at 1.3–2 μg/mL 3
† 0.62228 ± 0.33465‡ 25.50 ± 5.60§ 127.53/77.33 ± 11.51/4.38¶
5. Naïve VWD 2 2.0890, 2.1625‡ 10.60, 33.80 119.04/66.06, 104.47/57.88¶
ARFI = acoustic radiation force impulse; VWD = Willebrand disease.
*
ARFI time to hemostasis is defined as that required to bleed 75% of the total detected area of hemorrhage.
†
Mean from two separate procedures on each dog. No additional plasma therapy was required in these dogs.
‡
Mean bleeding rate comparisons 1 vs. 2 (p < 0.196), 1 vs. 3 (p <0.952), 1 vs. 4 (p < 0.970), 1 vs. 5 (p < 0.0009).
§
Time to hemostasis comparisons 1 vs. 2 (p < 0.00078), 1 vs. 3 (p < 0.036), 1 vs. 4 (p < 0.025), 2 vs. 4 (p < 0.027).
¶
Blood pressure comparisons 1 vs. 2 (p < 0.508), 1 vs. 3 (p < 0.704), 1 vs. 4 (p < 0.445), 1 vs. 5 (p < 0.391).
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